drugset
drugset / Trial / NCT07780383

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

NCT07780383 ↗

Phase 1 Recruiting 84 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration

Timeline

Start
2026-08-21
Primary completion
2027-06-17
Completion
2027-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986446 Monoclonal antibody — Intravenous

Indications

Alzheimer disease